Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been.
Clarity s theranostic prostate cancer trial advances to highest dose level sydneysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sydneysun.com Daily Mail and Mail on Sunday newspapers.
Clarity s theranostic prostate cancer trial advances to highest dose level vietnamtribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietnamtribune.com Daily Mail and Mail on Sunday newspapers.
Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy.
Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq. No dose limiting toxicities (DLTs) have been reported in cohort 1. The Safety Review Committee (SRC) has recommended that the trial continues to cohort 2. Recruitment has opened at clinical sites in the United States (US) at the cohort 2 dose level of 8GBq and patients are currently in screening for all available slots. Additional therapy cycles of 67Cu SAR-bisPSMA have been requested by clinicians under the US Food and Drug Administration (FDA) Expanded Access Program (EAP). Early data from the EAP indicates positive effects of the lowest dose of 67Cu SAR-bisPSMA on lesions, demonstrated by SPECT-CT images, with reduction in Prostate Specific Antigen (PSA) levels. SYDNEY, May 24, 2023 /PRNewswire/ Clarity Pharmaceuticals(ASX: CU6) ("Clarity", "the Company&quo